CDC Guideline Summary: Treatment and Management of Ocular Syphilis and Neurosyphilis

1. Core Treatment Principles

• Ocular syphilis is classified as central nervous system involvement and must be treated with the same neurosyphilis regimen regardless of cerebrospinal fluid (CSF) findings. 1

2. Recommended Antimicrobial Regimens

2.1 Preferred Regimen

• Aqueous crystalline penicillin G 18–24 million units per day administered intravenously (3–4 million units every 4 hours or continuous infusion) for 10–14 days. 1

2.2 Alternative Regimen (when adherence can be ensured)

• Procaine penicillin 2.4 million units intramuscularly once daily plus probenecid 500 mg orally four times daily for 10–14 days.
• Patients with sulfa allergy must not receive probenecid due to risk of allergic reaction. 2

2.3 Optional Adjunctive Therapy

• After completing the 10–14 day course, benzathine penicillin 2.4 million units intramuscularly once weekly for up to 3 weeks may be given to achieve a total treatment duration comparable to late‑latent syphilis. 1

3. Cerebrospinal Fluid (CSF) Evaluation

• All patients with ocular syphilis should undergo a CSF examination, irrespective of HIV status, to detect concurrent neurologic involvement. 1
• CSF abnormalities are reported in 10 %–60 % of ocular syphilis cases, and up to 50 % have a reactive VDRL in CSF. 3

4. Management of Penicillin Allergy

• Penicillin desensitization is the preferred strategy for patients allergic to penicillin who have neurosyphilis or ocular syphilis. 2
• If desensitization is not feasible, ceftriaxone 2 g daily (IV or IM) for 10–14 days is an alternative, but clinicians should be aware of possible cross‑reactivity with penicillin and consider skin testing when safety is uncertain. 2

5. Multidisciplinary Care

• Management of ocular syphilis must involve collaboration with an ophthalmologist to ensure appropriate ocular assessment and follow‑up. 1
• All individuals diagnosed with syphilis should be tested for HIV. 1

6. Monitoring and Follow‑Up

6.1 CSF Follow‑Up

• If initial CSF shows pleocytosis, repeat lumbar puncture every 6 months until the cell count normalizes.
• CSF leukocyte count is the most sensitive indicator of therapeutic response.
• Consider retreatment if cell count has not decreased after 6 months or if CSF cell count or protein remains abnormal after 2 years. 1

6.2 Serologic Monitoring

• Quantitative non‑treponemal tests (e.g., RPR) should be performed at 3, 6, 9, 12, and 24 months post‑therapy. 2
• In immunocompetent patients and HIV‑infected patients on effective antiretroviral therapy, normalization of serum RPR titers predicts normalization of CSF parameters. 1

7. Special Considerations for HIV‑Positive Patients

• The treatment regimen is identical for HIV‑positive and HIV‑negative patients with neurosyphilis or ocular syphilis. 2
• HIV‑positive individuals with clinical or laboratory evidence of neurosyphilis should receive aqueous crystalline penicillin G 18–24 million units IV daily. 2

8. Outcomes and Prognosis

• Early treatment yields a high therapeutic response in both HIV‑infected and uninfected patients. 3
• Delayed diagnosis is associated with poorer visual outcomes, especially when symptom duration is prolonged or baseline visual acuity is low. 3

Ocular Syphilis – CDC‑Based Clinical Guidelines

Treatment Regimen

• Intravenous aqueous crystalline penicillin G – Administer 18–24 million units per day (3–4 million units IV every 4 hours or continuous infusion) for 10–14 days. This regimen is identical to that for neurosyphilis and is the CDC’s standard of care. 4
• Alternative IM regimen (when adherence can be ensured) – Procaine penicillin 2.4 million units IM once daily plus probenecid 500 mg orally four times daily for 10–14 days. Patients with sulfa allergy should avoid this regimen because probenecid may trigger a reaction. 5
• Optional follow‑up benzathine penicillin – Some experts advise giving benzathine penicillin 2.4 million units IM weekly for up to 3 weeks after the IV/IM course to match the total therapy duration used for late‑latent syphilis. 4

Mandatory Cerebrospinal Fluid (CSF) Evaluation

• CSF examination is required for all patients with ocular syphilis, regardless of HIV status, to detect neuro‑involvement. 4
• Abnormal CSF findings (e.g., pleocytosis, elevated protein) mandate repeat CSF testing to monitor therapeutic response. 4

Multidisciplinary Ophthalmology Management

• Patients presenting with syphilitic ocular disease (e.g., uveitis, neuroretinitis, optic neuritis) should be co‑managed with an ophthalmologist to ensure appropriate ocular assessment and follow‑up. 4

HIV Screening

• Universal HIV testing is recommended for every individual diagnosed with syphilis, including those with ocular involvement. 4

Alternatives for Penicillin Allergy

• Ceftriaxone – Limited data support 2 g daily (IV or IM) for 10–14 days as an alternative for neurosyphilis/ocular syphilis. Cross‑reactivity with penicillin can occur; skin testing is advised when safety concerns exist. 4
• Penicillin desensitization – When a true penicillin allergy is present, CDC recommends desensitization followed by the standard penicillin regimen rather than using alternative agents. 5

Follow‑Up and Monitoring

• CSF monitoring – If the initial CSF shows pleocytosis, repeat lumbar puncture every 6 months until the leukocyte count normalizes; leukocyte count is the most sensitive marker of treatment success. Consider retreatment if cell count has not decreased after 6 months or if CSF abnormalities persist beyond 2 years. 4
• Serologic monitoring – Obtain quantitative non‑treponemal test titers at 3, 6, 9, 12, and 24 months post‑therapy to assess clinical response. 5

Common Pitfalls to Avoid

• Do not rely on intramuscular benzathine penicillin alone for ocular syphilis; this regimen is insufficient because ocular disease is considered central nervous system involvement and requires neurosyphilis‑level therapy. 4
• Do not delay treatment while awaiting CSF results; initiate therapy promptly based on clinical suspicion and serologic confirmation. 4
• Avoid procaine penicillin without probenecid, as it fails to achieve adequate CSF penicillin concentrations for neurosyphilis treatment. 5

Evidence Quality

• The recommendations are derived from CDC’s MMWR Recommendations and Reports (1998, 2002, 2004, 2010) and are supported by FDA drug‑labeling information, reflecting a high level of evidence and consistent guideline updates. [4][5]6

Guideline Recommendations for Ocular Syphilis and Neurosyphilis Treatment

Preferred Intravenous Regimen

• The CDC recommends aqueous crystalline penicillin G 18–24 million units per day administered intravenously (3–4 million units every 4 hours or by continuous infusion) for 10–14 days in all patients with ocular syphilis or neurosyphilis, regardless of HIV status. 7, 8, 9, 10

Identical Regimen for HIV‑Positive and HIV‑Negative Patients

• The same intravenous penicillin G schedule is indicated for both HIV‑positive and HIV‑negative individuals. 10

Alternative Outpatient Regimen (when adherence can be ensured)

• Procaine penicillin 2.4 million units intramuscularly once daily plus probenecid 500 mg orally four times daily for 10–14 days is an acceptable alternative. 7, 8, 9
• Patients with sulfa allergy must not receive probenecid because of the risk of cross‑reactivity. 7, 8
• Procaine penicillin without probenecid fails to achieve adequate cerebrospinal‑fluid (CSF) concentrations and should be avoided. 11

Optional Adjunctive Therapy

• Some clinicians add benzathine penicillin 2.4 million units intramuscularly weekly for up to three weeks to equal the total treatment duration used for late‑latent syphilis. Evidence level: CIII (low consensus). 7, 11

Management of Penicillin Allergy

• Penicillin desensitization is the preferred strategy for patients allergic to penicillin who have ocular syphilis or neurosyphilis. 7, 8, 11
• If desensitization is not feasible, ceftriaxone 2 g daily (IV or IM) for 10–14 days may be used, although data on efficacy are limited and there is potential for cross‑reactivity with penicillin. 7, 8, 10, 11
• Other alternative regimens have not been adequately evaluated and should not be employed. 7

Universal HIV Testing

• All individuals diagnosed with syphilis should undergo HIV testing. 9

Specialist Consultation

• Referral to an infectious‑disease specialist is recommended for complex cases of ocular syphilis or neurosyphilis. 7, 10

Cerebrospinal‑Fluid (CSF) Monitoring

• If the initial CSF shows pleocytosis, repeat lumbar puncture every 6 months until the white‑cell count normalizes. 8, 9
• Consider retreatment if the CSF cell count has not decreased after 6 months or if CSF abnormalities persist beyond 2 years. 8, 9

Serologic Follow‑up

• Perform quantitative non‑treponemal tests (RPR/VDRL) at 3, 6, 9, 12, and 24 months after completing therapy. 7, 10
• Approximately 15–20 % of patients enter a “serofast” state with low, stable titers (generally < 1:8); this pattern usually does not indicate treatment failure. 7, 8, 10
• Reinfection is defined by a ≥ four‑fold rise in titer above the established serofast baseline. 7, 10

Special Considerations for HIV‑Positive Patients

• The treatment regimen (IV penicillin G 18–24 million units daily for 10–14 days) is the same as for HIV‑negative patients. 10
• Retrospective studies show that HIV co‑infection is associated with poorer CSF and serologic responses to therapy. 8, 10
• HIV‑positive individuals may have a modestly increased risk of therapeutic failure and neurologic complications, though the absolute risk is low. 8

Guideline Recommendations for Ocular Syphilis Management

Treatment Regimens

• Primary therapy: Treat ocular syphilis as neurosyphilis with aqueous crystalline penicillin G administered intravenously at a total dose of 18–24 million units per day (either 3–4 million units IV every 4 hours or continuous infusion) for 10–14 days, irrespective of cerebrospinal‑fluid (CSF) findings or HIV status. CDC recommendation. [12][13]14
• HIV status: The same penicillin G regimen is used for both HIV‑positive and HIV‑negative patients. CDC recommendation. 15
• Alternative regimen (when adherence can be ensured): Procaine penicillin 2.4 million units intramuscularly once daily plus probenecid 500 mg orally four times daily for 10–14 days. CDC recommendation. [12][13]14
• Critical contraindication: Patients with sulfa‑drug allergy must not receive probenecid because of the risk of allergic reaction. CDC recommendation. 15
• Optional adjunctive therapy: After completing the 10–14‑day IV course, some clinicians give benzathine penicillin 2.4 million units IM weekly for up to 3 weeks, matching the total duration used for late‑latent syphilis. CDC recommendation. [12][13]14

Cerebrospinal‑Fluid (CSF) Evaluation

• Mandatory lumbar puncture: All patients with ocular syphilis should undergo CSF examination regardless of HIV status. CDC recommendation. 14
• Purpose of CSF testing: Identifies individuals who require CSF follow‑up to monitor therapeutic response. CDC recommendation. [12][13]14

Management of Penicillin Allergy

• Preferred strategy: Penicillin desensitization is the recommended approach for patients allergic to penicillin who have ocular syphilis or neurosyphilis. CDC recommendation. [15][14]
• Alternative antibiotic: Ceftriaxone 2 g daily (IV or IM) for 10–14 days may be used when desensitization is not feasible. CDC recommendation. 15
• Safety note: Because of possible cross‑reactivity with penicillin, perform skin testing when there are concerns about ceftriaxone safety. CDC recommendation. 15

HIV Screening

• Universal testing: Every individual diagnosed with syphilis should be screened for HIV. CDC recommendation. [12][13]14

Follow‑up and Monitoring

• CSF follow‑up: If initial CSF pleocytosis is present, repeat lumbar puncture every 6 months until the leukocyte count normalizes. CDC recommendation. [12][13]14
• Criteria for retreatment: Consider retreatment if (a) CSF cell count has not decreased after 6 months, or (b) CSF abnormalities persist beyond 2 years. CDC recommendation. [12][13]14
• Serologic monitoring: Perform quantitative non‑treponemal tests (RPR/VDRL) at 3, 6, 9, 12, and 24 months after therapy. CDC recommendation. 15
• Serofast state: Approximately 15–20 % of patients enter a serofast condition with low, stable titers (generally < 1:8); this usually does not indicate treatment failure. CDC recommendation. 15
• Definition of reinfection: A ≥ 4‑fold rise in non‑treponemal titer above the established serofast baseline defines reinfection. CDC recommendation. 15